Houston's density is possibly its biggest challenge when it comes to developing its innovation ecosystem, says a Houston expert. Getty Images

From the front porch of Houston, Texas, we solve some of humanity's hardest challenges. We're the ones who put humans on the Moon and rovers on Mars, go subsea in search of hydrocarbons, and are discovering a cure for cancer. We solve complex challenges, because of a characteristic seemingly embedded deep within our DNA — we are all explorers of the unknown.

Today, a new challenge is rallying our attention, inspiring us to push the boundaries yet again. And, that's the hard challenge of population density. Houston is fourth in population in the country, and yet 89th in the number of people per unit of area.

Why is this an issue, one might ask? Houston, like many other cities around the world, is racing to become a hub for innovation, a critical catalyst fueling the next generation of growth and economic prosperity. And, density is a key component of innovation — it brings divergent mindsets together to look at challenges from multiple perspectives and creates an environment that brings big bold ideas to life.

However, the nature of our geography has created silos that are not easily broken down and separates us by industries, communities, interests, mindsets, and access to transportation, among other things.

But, let's not underestimate our true spirit — and our ability to explore the unexpected, push the boundaries and tackle the challenges the world throws at us.

If I learned anything from living here my entire life, Houston has grit, imagination, and motivation and knows what it means to be a trailblazer. Houston is the most diverse city in the United States. Our culinary landscape is constantly pushing the boundaries of creativity and imagination. Local graffiti and modern art installations are reshaping the visual identity of our community. Our sports and performing arts "rockstars" consistently deliver real-time experiential immersion.

We need to recognize and embrace how these colors of Houston connect us all regardless of our geographic silos and push innovation forward. Said another way, we have all the colors; we just need to converge and paint the canvas together.

True to our nature, some of our Houstonian friends have begun chipping away at this challenge already. Central Houston is attracting world-renowned incubators and accelerators like MassChallenge and Gener8tor — and this scene alone is ever-expanding. The Cannon, The Ion, Impact Hub, Launchpad, Headquarters, and other players are creating environments that bring people together and meet the needs of an ever-evolving workforce through experiential community. We even have a dedicated publication for all things innovation — Innovation Map — sharing resources across our vast city and ensuring no great story is left untold.

Our rich diversity means we have access to human beings from a multitude of backgrounds, which in itself is a force to be reckoned with. By interacting with a variety of human beings, we become more empathetic, understanding, and celebratory of new ideas. This is fundamental to continuous innovation — how we interact and approach challenges, engage in new experiences, and become an inspirational leader in life and work. So, break down the silos and access the diversity of thinking that's already outside the door.

At the same time, the challenge of density must be tackled not only physically but also digitally. By converging the physical and digital ecosystem through a neural network, we can intelligently connect the activity with centralized access to start-ups, corporations, nonprofits, free-lancers, incubators, accelerators, maker-spaces, academia, local influencers, and public partners. Digitally bridging all of us can make one of the largest and most spread-out cities in the U.S. feel like a small Texas town with big ideas and an ever-stronger dimension of inclusivity.

So, join the movement, strike up a conversation, grab your metaphorical spray paint and converge with all the vibrant colors of Houston as we energize the future of humanity, navigate to Mars and back safely, and annihilate the existence of cancer.

As Steve Jobs said: "The people who are crazy enough to think that they can change the world, are the ones who do." Are we ready?

------

Brad Rossacci is creative director at Accenture's Innovation Hub in Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.